Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of METREX and METREO Patient-Reported Outcomes, Response to Therapy and Lung Function
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Conference item |
Veröffentlicht: |
American Thoracic Society
2018
|